James Pham

Dr. James Pham


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Melanoma Research
Verified
Journal Article
Closed access
JPJames Pham
James Pham
LOLawrence On
Lawrence On
LALuke Ardolino
Luke Ardolino
JHJoshua Hurwitz
Joshua Hurwitz
HSHelene Salaun
Helene Salaun
AJAnthony M. Joshua
Anthony M. Joshua
Metastatic uveal melanoma (mUM) has historically been associated with short survival and limited effective treatments. Immune checkpoint inhibitors (ICIs) have been trialed in mUM; however, robust conclusions regarding their efficacy are difficult to draw given small study sizes and heterogeneous patient populations. Five databases were searched using a combination of ‘ICI’ and ‘mUM’ headings, and data on patient demographics, objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) were extracted. Pooled ORR was calculated using a random effects model and the inverse variance method. Available Kaplan–Meier OS and PFS curves were used to construct summary OS and PFS plots, from which median values were derived. Pooled ORR was 9.2% overall (95% CI 7.2–11.8) [4.1% for anti-CTLA4 (95% CI 2.1–7.7), 7.1% for anti-PD(L)1 (95% CI 4.5–10.9) and 13.5% for anti-CTLA4 plus anti-PD1 (95% CI 10.0–18.0)]. Median OS was 11.5 months overall (95% CI 9.5–13.8) [8.0 months for anti-CTLA4 (95% CI 5.5–9.9), 11.7 months for anti-PD(L)1 (95% CI 9.0–14.0) and 16.0 months for ipilimumab plus anti-PD1 (95% CI 11.5–17.7) (P <0.001)]. Median PFS was 3.0 months overall (95% CI 2.9–3.1). ICIs have limited efficacy in mUM and a recommendation for their use must consider the balance of benefit and risk for individual patients if no other options are available. Further biomarker profiling studies may be helpful in assessing which patients will benefit from ICIs, in particular the addition of ipilimumab to anti-PD1 therapy.

16 November 2023 in Experimental Dermatology
Verified
Journal Article
Open access
JPJames Pham
James Pham
ARAnthony Rodrigues
Anthony Rodrigues
SGSimone M. Goldinger
Simone M. Goldinger
Hao-Wen SimHao-Wen Sim
Hao-Wen Sim
JLJia Liu
Jia Liu
Patients with advanced cutaneous squamous cell carcinoma (cSCC) who are not eligible for or who fail to respond to anti‐PD1 immunotherapy have few treatment options. Epidermal growth factor receptor (EGFR) inhibitors have been investigated as a therapeutic option for advanced cSCC; however, data are limited to small single‐arm trials or retrospective studies. A systematic review and meta‐analysis was conducted to PRISMA guidelines (CRD42023394300). Studies reporting on outcomes of EGFR inhibition in advanced cSCC were identified. Objective response rate (ORR), progression‐free survival (PFS), overall survival (OS) and adverse event (AE) rate were pooled using a random effects model and the inverse variance method. Twelve studies (six prospective, six retrospective) were identified, representing 324 patients. Pooled ORR was 26% (95% confidence interval [CI] 18–36), median PFS was 4.8 months (95% CI 3.9–6.6) and median OS was 11.7 months (95% CI 9.2–14.1). Any grade AEs occurred in 93% of patients (95% CI 85–97) while grade 3 and higher AEs occurred in 30% (95% CI 14–54). These results were similar between anti‐EGFR monoclonal antibodies (MAbs) and tyrosine kinase inhibitors (TKIs). EGFR inhibitors can be considered in patients with advanced cSCC who are contraindicated for or progress on first‐line anti‐PD1 immunotherapy. Future studies should evaluate their activity and safety following anti‐PD1, identify predictive biomarkers for their efficacy and explore combination approaches.

1 September 2022 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JPJames Pham
James Pham
PSPhoebe Star
Phoebe Star
KPKevin Phan
Kevin Phan
YLYanni Loh
Yanni Loh
AJAnthony M. Joshua
Anthony M. Joshua
ASAnnika Smith
Annika Smith

14 November 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AFAkshay Flora
Akshay Flora
JPJames Pham
James Pham
JWJane A. Woods
Jane A. Woods
MRMichael Radzeika
Michael Radzeika
HDHugh Dickson
Hugh Dickson
JFJohn Frew
John Frew

5 May 2022 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
JPJames Pham
James Pham
PSPhoebe Star
Phoebe Star
LALuke Ardolino
Luke Ardolino
ASAnnika Smith
Annika Smith
AJAnthony Joshua
Anthony Joshua

21 September 2022 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
JPJames Pham
James Pham
NANicholas Allen
Nicholas Allen
ASAnnika Smith
Annika Smith